PPCB (Propanc Biopharma) Capex-to-Operating-Cash-Flow: (As of Mar. 2026)

Propanc Biopharma  (NAS:PPCB) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.

Propanc Biopharma Capex-to-Operating-Cash-Flow Related Terms

The historical data trend for Propanc Biopharma's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Propanc Biopharma Capex-to-Operating-Cash-Flow Chart

Propanc Biopharma Annual Data
	Trend	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23	Jun24	Jun25
Capex-to-Operating-Cash-Flow		Get a 7-Day Free Trial					-	-	-	-	-

Propanc Biopharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Capex-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

PPCB vs ARTL, GNPX, BCAB: Capex-to-Operating-Cash-Flow Comparison

For the Biotechnology subindustry, Propanc Biopharma's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Propanc Biopharma Capex-to-Operating-Cash-Flow vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Propanc Biopharma's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Propanc Biopharma's Capex-to-Operating-Cash-Flow falls into.

Propanc Biopharma Capex-to-Operating-Cash-Flow Calculation

Propanc Biopharma's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Jun. 2025 is calculated as

Propanc Biopharma's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Propanc Biopharma Business Description